Coming Off Compounded Semaglutide: How the Transition Works

If you got an email saying your compounded semaglutide program is ending, you are part of a very large group. The mass-market compounded GLP-1 business was built on a temporary legal opening, and that opening has been closing since early 2025.

The good news: moving to an FDA-approved product is usually straightforward, and cash prices for the approved versions have fallen dramatically since 2024. The part that trips people up is the dose. There is no official conversion chart from a compounded product to a brand product, for reasons that are worth understanding rather than working around.

This article explains why the market changed, what makes the dose question genuinely hard, and how the transition works in practice. Where it describes dosing, missed doses or reinitiation, it is summarizing the FDA-approved prescribing information and Instructions for Use for the approved products - not giving instructions. It is not medical advice and it does not tell you what dose to take. Follow the prescription you are given and the directions from your own prescriber and pharmacist.

Why is compounded semaglutide disappearing?

Compounding a copy of a commercially available drug is normally not allowed. The exception that created this entire market was the FDA drug shortage list: while a drug is in shortage, compounders may make versions of it.

The timeline:

• February 21, 2025: FDA declared the shortage of all doses of injectable semaglutide resolved. It gave 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop compounding, distributing and dispensing semaglutide injection products, saying the staged dates were meant to avoid unnecessary disruption to patient treatment [1].
• February 6, 2026: FDA announced it would restrict GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs mass-marketed as alternatives to approved medicines, and would pursue misleading direct-to-consumer advertising, warning that failure to correct violations could bring seizure or injunction without further notice [2].
• April 1, 2026: FDA issued its first express statement of when a compounded GLP-1 counts as “essentially a copy” of a commercially available drug - the same active ingredient at the same, similar or easily substitutable strength usable by the same route, unless the prescriber determines and documents a change producing a significant difference for that specific patient [3].
• April 30, 2026: FDA proposed not including semaglutide, tirzepatide or liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substance. The public comment docket closed on June 29, 2026, and as of September 14, 2026 FDA has not announced a final determination. If finalized, that closes large-scale 503B compounding of these three even in a future shortage [4].

That last point matters for planning. The April 2026 proposal is not about today’s shortage status; it is about removing the mechanism that would allow this to restart.

Meanwhile, FDA has logged more than 1,700 adverse event reports naming compounded GLP-1s through May 31, 2026 - about 990 for compounded semaglutide and more than 730 for compounded tirzepatide - a figure the agency notes is likely an undercount because state-licensed 503A pharmacies are not required to report [5].

Why can’t I just switch to the same milligram dose?

Three reasons, and each one is a real clinical problem rather than bureaucratic caution.

1. Compounded products were not standardized. Two vials labeled the same milligram strength could differ in concentration, in what else was in them, and in how much active drug you actually received per injection. After the shortage ended, many compounders and telehealth platforms kept selling semaglutide by adding a second ingredient - cyanocobalamin (vitamin B12), glycine or niacinamide - or by offering doses that do not exist in the approved pen, and marketing the result as personalized medicine [6].

2. Some products used a different active ingredient. FDA has warned that some compounded and gray-market products contain semaglutide sodium or semaglutide acetate rather than the semaglutide base used in Ozempic, Wegovy and Rybelsus. FDA considers these different active ingredients and says it has no information on whether they share the chemical and pharmacologic properties of the approved ingredient [7]. If your product was a salt form, the milligram number on the label does not translate cleanly.

3. The approved doses are fixed and yours may not match. Wegovy injection comes in exactly six strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg (Wegovy HD) [8]. Zepbound comes in 2.5, 5, 7.5, 10, 12.5 and 15 mg [9]. Compounded vials were commonly dialed to intermediate amounts - 0.75 mg, 1.2 mg, 1.5 mg - that sit between label steps. Someone at a compounded 1.2 mg weekly falls between the 1 mg and 1.7 mg Wegovy pens, and a prescriber has to choose which side to land on.

There is a separate safety reason FDA cares about vial dosing. The agency has alerted providers, compounders and patients to overdoses from dosing errors with compounded injectable semaglutide supplied in vials - patients drawing the wrong volume and clinicians miscalculating doses, in some cases producing 10-fold overdoses that led to nausea, vomiting, abdominal pain, dehydration, fainting, gallstones, pancreatitis and hospitalization [10]. If the dose on your vial label and the dose you actually drew ever diverged, that is exactly the kind of uncertainty your prescriber needs to hear about.

None of this means the transition is dangerous. It means the dose is a clinical judgment, not a lookup.

What actually has to happen to move to a brand product?

The mechanics, in order:

1. Get a new prescription. A compounded prescription is written for a specific compounding pharmacy and a specific non-FDA-approved formulation. It does not transfer. To receive Wegovy, Ozempic, Zepbound or Mounjaro through any channel - a retail pharmacy, a manufacturer direct-to-patient program, or a telehealth platform - a prescriber has to write a fresh prescription for the FDA-approved product.

2. Pick the matching molecule if you can. GoodRx’s transition guidance makes the simple point: staying with the same active ingredient gives the prescriber the most to work with. Compounded semaglutide maps to Wegovy (weight management) or Ozempic (type 2 diabetes); compounded tirzepatide maps to Zepbound or Mounjaro. Moving to a different molecule is a bigger change and usually means a fresh titration [11].

3. Let the prescriber set the dose. Bring the evidence (below) and let them map it. GoodRx’s guidance is explicit that compounded products “may not match a branded option exactly,” so the prescriber finds the closest equivalent, which “may involve starting at a lower dose and gradually increasing it, especially if you previously experienced side effects” [11].

4. The labels address overlap. The Wegovy label states, under Limitations of Use, that concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended [8]. The Zepbound label carries the mirror statement for tirzepatide [9]. In practice that is why prescribers treat the compounded product and the approved product as sequential rather than overlapping, and why “finishing the vial” while starting the pen is not how these transitions are written. The timing is set by the prescription you are given.

5. Sort the money before the last vial. Prior authorization can take one to three weeks. Starting the conversation with a couple of weeks of supply left is a lot less stressful than starting it with none.

What should I bring to the appointment?

A prescriber deciding where to restart you is reconstructing your exposure history. Make it easy:

• The vial or the pharmacy label, or a clear photo of it. This shows the concentration, the compounding pharmacy and any added ingredients.
• Your injection volume, not just the milligram number - how many units you drew each week.
• Whether the product was a salt form if the label says so (semaglutide sodium, semaglutide acetate).
• Your current weekly dose and how long you have been on it.
• The exact date of your last injection.
• How you tolerated each step up. “Rough two weeks when I moved up, fine after” is precisely what shapes the answer.
• Your weight trend over the last three months, including any plateau or recent regain.
• Insurance card and any prior denial letters.
• Whether you would prefer a pen, a vial or a tablet. There is now an oral option for semaglutide as well as injections.

How long should I wait between the last compounded dose and the first brand dose?

No FDA label sets a washout period for moving from a compounded product to the approved version of the same molecule. What the labels do say is: one GLP-1 at a time [8][9].

Semaglutide has a half-life of about one week, which is why a normal weekly interval keeps drug levels roughly steady through the switch. The practical judgment your prescriber makes is whether to keep your normal weekly rhythm or to leave a longer gap, based on your tolerance history, the reliability of what you were taking, and any side effects.

If you have already been off for a while, say so specifically. The current Wegovy prescribing information says that if two or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [8]. That instruction exists because gastrointestinal tolerance fades during a break. There is a published case report of a 51-year-old woman who had tolerated semaglutide for about a year, paused five weeks, restarted at her old 2.4 mg maintenance dose, and was hospitalized for four days with severe nausea, vomiting, diarrhea and electrolyte abnormalities. Her clinicians restarted her two weeks later at a lower dose with gradual escalation, and argued in print that reinitiation after a prolonged interruption should begin lower [12].

Health-system protocols codify the same logic. The Beth Israel Lahey Health GLP-1 RA Conversion Guide suggests, for someone resuming subcutaneous semaglutide 1 mg weekly, restarting at 1 mg if fewer than two doses were missed, 0.5 mg if three to four were missed, and 0.25 mg if more than five were missed [13]. That is one institution’s operational reading of the label, not an FDA instruction - but it shows how clinicians think about gaps.

What does the brand version cost now?

This is the part that has changed most, and mostly in patients’ favor. As of September 2026:

Semaglutide (Novo Nordisk self-pay through NovoCare):

• Wegovy pens: $349 per month standard, $399 for the 7.2 mg high dose. New self-pay patients pay $199 per month for the 0.25 mg or 0.5 mg starter doses for the first two fills, an offer running through December 31, 2026 [14].
• Wegovy tablets: $149 per month for 1.5 mg, $199 for 4 mg, $299 for 9 mg and 25 mg [14].
• Subscription plans through telehealth partners, launched March 31, 2026: $329 per month on a 3-month plan, $299 on 6 months, $249 on 12 months for pens [15].

Tirzepatide (Eli Lilly Zepbound Self Pay Journey Program):

• $299 per month for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg through 15 mg - the $449 tier conditional on refilling within 45 days of the previous delivery. Lilly’s published terms list the regular self-pay price for a one-month supply as $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg and 15 mg; the 2.5 mg and 5 mg tiers carry no refill condition. Vials and the single-patient-use KwikPen are priced the same at every strength, and a “month” is defined as 28 days [16][18].

For comparison, compounded semaglutide from telehealth platforms and 503A pharmacies has typically been advertised between roughly $99 and $499 per month in 2026, with the lowest prices tied to long-term prepaid plans and starter doses.

Two things worth knowing before you choose a channel:

• Self-pay money does not count toward your deductible or out-of-pocket maximum. Novo Nordisk, Eli Lilly and the federal TrumpRx site all say so, and you generally cannot submit the claim for reimbursement [17].
• Telehealth membership fees stack on top of medication cost. If you already have a prescriber willing to write the prescription, using them and filling through a manufacturer self-pay channel or your insurance avoids the subscription layer entirely.

See this site’s access and pricing coverage for the full picture, including Medicare, employer coverage and appeals.

What about just buying peptides online instead?

Short answer: no.

A parallel, prescription-free market sells semaglutide, tirzepatide, retatrutide and other peptides as lyophilized powders labeled “research use only, not for human consumption.” These are not medicines. They are not made to pharmaceutical standards, they are not tested for potency or sterility as a drug would be, and selling them for human use is not legal.

FDA has issued warning letters to research-use-only peptide sellers, and in August 2026 the Mississippi State Board of Medical Licensure, Board of Nursing and Board of Pharmacy jointly barred providers from using research-grade peptides. The FDA’s growing adverse-event tally for compounded GLP-1s - more than 1,700 reports through May 2026 - comes disproportionately from products outside the normal supply chain [5].

If cost is the reason you are considering it, the manufacturer self-pay prices above are now in the same range as many compounded programs, and a prescriber can help with prior authorization if insurance is an option.

What are people most worried about when they switch?

“Will I gain the weight back during the transition?” A short, well-managed handoff should not produce meaningful regain - semaglutide’s week-long half-life means levels fall slowly. A long gap is a different matter. Trial data shows regain is front-loaded after stopping, so the fix is to avoid the gap, not to stockpile.

“My compounded dose felt stronger/weaker than the brand.” That is a documented possibility, not a sign anything is wrong with you. Concentration and formulation varied between compounded products, and some used salt forms FDA treats as different active ingredients [7]. Report the difference to your prescriber rather than adjusting on your own.

“Do I have to start over at 0.25 mg?” Not necessarily, but it depends on your documented dose, your tolerance history, how reliable the product was, and how long any gap has been. A prescriber with poor documentation to work from will reasonably be more conservative. That is why bringing the vial label matters.

“My telehealth platform switched me automatically.” Many large platforms moved to branded prescribing during 2025 and 2026. Check what product you are actually being sent, at what dose, and confirm it matches what you discussed. A prescription for an FDA-approved product should name the brand and the strength.

What is the bottom line?

The compounded GLP-1 era is ending because the legal condition that created it - a drug shortage - is gone, and FDA has moved to keep it closed. Moving to an approved product means a new prescription, a dose that a prescriber maps by hand from your history rather than from a chart, and no overlap between products. Bring your vial label, your injection volume, your dose history and the date of your last shot. Sort out coverage or self-pay before your supply runs out. And if you have already been off for more than a couple of weeks, say so plainly - that changes where a careful prescriber will restart you.

Sources

1. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
2. FDA to restrict ingredients used in mass-marketed compounded GLP-1s, AJMC, February 2026
3. FDA clarifies policies for pharmacy compounders of GLP-1 products, Foley analysis, April 2026
4. FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, April 30, 2026
5. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide, Drug Discovery Trends
6. Microdosing GLP-1s: does it work? GoodRx
7. FDA’s concerns with unapproved GLP-1 drugs used for weight loss
8. Wegovy (semaglutide) US Prescribing Information, revised 06/2026
9. Zepbound (tirzepatide) US Prescribing Information, revised 08/2026
10. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
11. Switching from a Compounded GLP-1: A Step-by-Step Guide, GoodRx
12. Severe Gastrointestinal Intolerance After Resuming Maintenance-Dose Semaglutide Following Treatment Interruption, Cureus 2026
13. BILH GLP-1RA and Dual GLP-1RA/GIP Conversion Guide, Beth Israel Lahey Health
14. NovoCare Wegovy Price Guide
15. Novo Nordisk launches multi-month subscription program for Wegovy, March 31, 2026
16. Lilly lowers price for Zepbound single-dose vials, Eli Lilly investor release
17. NovoCare: Wegovy patient information
18. Zepbound (tirzepatide) Full Terms and Conditions - Zepbound Self Pay Journey Program, LillyDirect (regular self-pay prices by dose)